About Us
Home 
About Us
About Us
Home About Us
Our Legacy
Founded in 1946, PI has a rich legacy that is anchored around the core belief that ‘Science’ makes the difference. At PI, we believe that Science inspires, that Science catalyzes relationships, and that Science makes chemistry happen. Over the past 80 years, we have leveraged Science to make a difference in Life Sciences- whether it is plant health, animal health, environmental health, and more recently, human health.
PI Health Sciences, a subsidiary of PI, is a leading Contract Research, Development and Manufacturing Organization (CRDMO) with R&D and manufacturing locations in Europe (Italy), and India (Hyderabad, Panoli, Jaipur, Ankleshwar) providing end to end solutions from discovery through development and manufacturing for both its big pharma and biotech partners.
Our Vision
Our DNA
Lead with science, technology, and human ingenuity to create transformative solutions in life sciences.
Our DNA
COURAGEOUS
CURIOUS
CREATIVE
CARING
Our Journey
Driven By Science From Innovation To Impact
Message From Our Chairman
We will pave the way for building a differentiated position in the pharma value chain by technology partnerships, selecting niche product portfolio, leveraging our competencies in complex chemistry, operational & commercial excellence, expanding global reach. Know More
Mayank Singhal
Vice Chairperson and Managing Director,
PI Industries
Message From Our Chairman
Mayank Singhal
Vice Chairperson and Managing Director,
PI Industries
We will pave the way for building a differentiated position in the pharma value chain by technology partnerships, selecting niche product portfolio, leveraging our competencies in complex chemistry, operational & commercial excellence, expanding global reach.
Ramesh Subramanian, Ph.D.
Global CEO
Dr. Ramesh has a Ph.D. in Chemical Engineering, MBA (finance) from The Wharton School and over 21 years of rich global experience in building businesses across Asia, Europe, and North America.
He has extensively worked on raising venture capital, implementing transformational strategies, driving M&A, and managing cross-border alliances. His expertise helps propel PI Health Sciences to greater heights.
Mahavir Prashad, Ph.D.
Chief Development Officer
Dr. Mahavir has a Ph.D. in Organic Chemistry from Central Drug Research Institute, Lucknow and brings over 35 years of global experience and expertise in the pharma industry. Over his career, Mahavir has been part of 71 patents/applications, 94 publications and 4 review articles and one book chapter.
He received the Heroes of Chemistry Award from the American Chemical Society in 2021 and was also awarded the Novartis Leading Scientist in 2002.
Simon Haydar, Ph.D.
Chief Scientific Officer
Dr. Simon has a Ph.D. in Organic Chemistry from the University of Vermont and completed a fellowship at Florida State University. He has over two decades of rich experience in the pharma industry where he led teams to develop novel oral therapies for Neuroscience, Oncology and Infectious Diseases.
Simon has authored multiple INDs and led the development of 8 clinical candidates into Phase 3. He holds 31 issued patents and has authored 49 publications and 5 review papers.
Alessio Piccoli
Chief Commercial Officer
Mr. Alessio has an MBA from LSE, London School of Economics and Political Science, and brings over 24 years of global experience and expertise in the pharma industry with a focus on innovation and speed in business development while emphasizing quality and safety.
Alessio has had an exemplary career in the pharmaceuticals Industry where he covered positions in R&D, pharmaceuticals trading, CRDMO & CMO, ans dossier and licensing businesses.
Franco Moro
Global Chief Operating Officer
Mr. Franco, brings nearly four decades of leadership experience in life sciences. A master’s in Chemical Engineering from the University of Padua and an MBA from SDA Bocconi have been earned by him, and global operations, business expansions, and industrial strategies across the US, China, and Italy have been successfully led under his guidance.
Growth and transformation, including the NYSE listing of Stevanato Group, were achieved during his tenure as CEO of FIS and Stevanato. A customer-centric approach and a focus on innovation and quality have defined his career, enabling the delivery of breakthrough medicines globally.